Beta Bionics (NASDAQ:BBNX) Downgraded by Wall Street Zen to “Strong Sell”

Wall Street Zen downgraded shares of Beta Bionics (NASDAQ:BBNX) from a hold rating to a strong sell rating in a research note published on Saturday morning,Wall Street Zen reports.

Several other equities research analysts also recently commented on the stock. Robert W. Baird upped their target price on shares of Beta Bionics from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Tuesday, September 15th. Bank of America boosted their price target on shares of Beta Bionics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Tuesday, September 15th. William Blair started coverage on shares of Beta Bionics in a research report on Friday, August 21st. They issued a “market perform” rating for the company. Weiss Ratings raised Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. Finally, Jefferies Financial Group assumed coverage on Beta Bionics in a report on Monday, October 12th. They set a “buy” rating and a $30.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Beta Bionics currently has an average rating of “Moderate Buy” and a consensus price target of $23.69.

Beta Bionics Trading Down 4.7%

Shares of BBNX stock opened at $16.75 on Friday. Beta Bionics has a 1 year low of $8.80 and a 1 year high of $32.71. The firm’s 50 day moving average is $19.11 and its 200-day moving average is $14.89. The firm has a market capitalization of $910.70 million, a price-to-earnings ratio of -9.10 and a beta of 3.39.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings data on Tuesday, October 27th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.01. Beta Bionics had a negative return on equity of 27.33% and a negative net margin of 65.31%. The firm had revenue of $35.51 million during the quarter. On average, equities research analysts forecast that Beta Bionics will post -2.03 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Stephen Feider sold 6,675 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $127,559.25. Following the completion of the transaction, the chief financial officer directly owned 159,378 shares of the company’s stock, valued at $3,045,713.58. This represents a 4.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark Hopman sold 30,779 shares of the stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $20.13, for a total value of $619,581.27. Following the transaction, the insider owned 56,479 shares of the company’s stock, valued at approximately $1,136,922.27. The trade was a 35.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 101,943 shares of company stock valued at $1,995,201. Corporate insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Beta Bionics

Hedge funds have recently made changes to their positions in the business. Legal & General Group Plc acquired a new position in Beta Bionics during the second quarter worth $62,000. The Manufacturers Life Insurance Company acquired a new stake in Beta Bionics in the 2nd quarter valued at $172,000. Ieq Capital LLC bought a new stake in Beta Bionics during the 2nd quarter worth about $229,000. Quantbot Technologies LP bought a new stake in Beta Bionics during the 2nd quarter worth about $264,000. Finally, Man Group plc acquired a new position in shares of Beta Bionics during the 2nd quarter worth about $419,000.

Key Stories Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Quarterly results slightly beat expectations. Beta Bionics reported a third-quarter loss of $0.52 per share, better than the $0.53 consensus estimate, while revenue of $35.51 million exceeded analysts’ expectations of approximately $34.7 million. The company also updated its 2026 guidance, although details were not provided. Beta Bionics third-quarter results
• Positive Sentiment: Analyst sentiment remains generally favorable. Stifel Nicolaus maintained a Buy rating, and several firms have raised price targets. MarketBeat data shows a Moderate Buy consensus and an average target of $23.69, above the recent trading level.
• Neutral Sentiment: Institutional ownership news was mixed but included notable purchases. BlackRock, Bank of America and other investment firms recently initiated or increased positions in Beta Bionics. Such activity may provide some support, but the reported purchases largely reflect earlier quarters rather than a new catalyst.
• Neutral Sentiment: Insiders continued to sell relatively small portions of their holdings. Director Mark Hopman sold 821 shares for about $16,420, while insider Mike Mensinger sold 2,650 shares for approximately $58,300. Both retained substantial positions, limiting the significance of the transactions, though repeated insider selling can weigh on investor sentiment. SEC insider filing
• Negative Sentiment: Multiple law firms reiterated a securities class-action deadline of November 3, 2026. The lawsuit covers investors who purchased BBNX securities from July 30, 2025, through February 24, 2026. The unusually large number of investor-law-firm notices increases legal, reputational and potential financial risks for Beta Bionics.
• Negative Sentiment: The allegations center on FDA compliance and iLet safety disclosures. Notices allege that Beta Bionics did not fully disclose information related to an FDA warning, quality-system issues and more than 18,000 iLet complaints, including potentially serious hypoglycemia incidents. These claims have not been proven, but possible litigation costs, regulatory action or additional product concerns could pressure the stock. Beta Bionics securities class action notice
• Negative Sentiment: Execution risks could cloud future growth. The company has disclosed challenges associated with the commercial launch of its next-generation Mint patch pump, adding uncertainty to its growth outlook.

Beta Bionics Company Profile

Beta Bionics, Inc (NASDAQ: BBNX) is a medical technology company focused on developing and commercializing automated insulin-delivery systems for people with insulin-dependent diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with limited user input.

The iLet Bionic Pancreas combines a wearable insulin pump with continuous glucose monitoring technology and adaptive dosing algorithms. The system is designed to automatically adjust insulin delivery based on an individual’s glucose readings and requires users to provide relatively simple meal announcements rather than calculate precise carbohydrate amounts.